Life Sciences Insights
Life sciences newsletter - Vol. 1 - Issue 6
Welcome to the sixth Belgian newsletter for the Life Sciences industry, published by Deloitte! We publish this newsletter every 2 months and we hope this will be an enjoyable and productive reading – please contact us if you have any questions or wish to discuss any of the topics further.
- Top-performing medical device companies can impact shareholder value with supply chain improvements, according to Deloitte Global Benchmarking Center study
Deloitte‟s Global Benchmarking Center (GBC) recently conducted a study on supply chain practices in medical device companies. The study shows that supply chain activities play a major role in shaping the four key drivers of shareholder value – revenue growth, operating margin, asset efficiency and customer service.
More top-performing medical device companies can impact shareholder value with supply chain improvements, according to Deloitte Global Benchmarking Center Study.
- Transatlantic economic integration and pharmaceuticals – overview on progress
At their April 2007 Summit meeting, the leaders of the United States of America and the European Union committed their governments to strengthening transatlantic economic integration and agreed on a “Framework for Advancing Transatlantic Economic Integration”. Pharmaceuticals and medical devices are two areas where regulatory cooperation has been on-going.
- Managing talent in a turbulent economy – Keeping your team intact
In 2009 Deloitte Consulting together with Forbes Insights conducted a year-long longitudinal talent series surveying global executives across all industries, at large businesses worldwide in the Americas, Asia Pacific, and Europe, the Middle East, and Africa.
In the month of August Deloitte carried out an additional study related to Talent Management in economic downturn.
- Lump sum financing of the hospital pharmacy: what has been the impact on patients, hospital and public health care payer?
Since July 2006, a partial prospective budget (i.e. lump sum) for pharmaceutical products administered to hospitalized patients in acute hospitals has been introduced in Belgium.
Today, a few years after the launch of the lump sum, the Belgian healthcare payer (RIZIV/INAMI) has performed an evaluation of the impact of the lump sum on the public healthcare payer itself and on hospitals and patients.
- Financial crisis and healthcare: bottleneck or window of opportunity?
A financial crisis, such as that we recently experienced, may affect public health at several possible levels. Over 600 health experts gathered in October to discuss this topical issue.
- Did you know?